Opinion|Videos|May 23, 2024
Lessons from EXPLORER-HCM: Unveiling CMIs' Potential in oHCM Treatment
Author(s)Anjali Tiku Owens, MD
A expert cardiologist delves into the insights gained from clinical trials assessing Cardiac Myosin inhibitors (CMIs) for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), with a particular focus on the EXPLORER-HCM trial, which investigated the efficacy and safety of mavacamten in managing oHCM.
Advertisement
Episodes in this series
- What have we learned from clinical trials evaluating CMI’s for oHCM?
Hutt et al 2024
- Mavacamten: Outcomes; focused on feel and function
Olivotto et al 2020 ,Maron et al 2023 - Longer-term outcomes of the VALOR-HCM RCT
Desai et al 2023 - MAVA-LTE
- Aficamten: phase 2 REDWOOD-HCM soon to be completed, phase 3 trial SEQUIOA-HCM.
Masri et al 2022 ,Maron et al 2023
Advertisement
Related to this article
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Two-year ICONIC-LEAD data show oral icotrokinra sustained PASI 90 and IGA 0/1 responses in more than 70% of adults and adolescents with plaque psoriasis.
New TOGETHER-PsO data show ixekizumab plus tirzepatide drove broader immune and metabolic biomarker changes than ixekizumab alone in psoriasis and obesity.
Jasmohan Bajaj, MD, joins Nancy Reau, MD, and Kim Brown, MD, to review what is new in the ACG hepatic encephalopathy guideline.
Lasker Award winners Takehisa Kitazawa and Tomoyuki Igawa discuss prophylaxis gains, remaining unmet needs, and lessons for drug discovery.
In the phase 3 RAPIDe-3 trial published in The Lancet, median time to symptom relief was 1.28 hours with deucrictibant vs more than 12 hours with placebo.
Lasker Award winners Kunihiro Hattori, Takehisa Kitazawa, and Tomoyuki Igawa recount the 2400 variants behind the drug.
Weltruza requires no loading doses, oral supplementation, or post-injection monitoring, with approval based on the phase 3 SOLARIS trial.
Advertisement
Advertisement
Trending on HCPLive
1
Tilrekimig Meets EASI-75 Goal in Atopic Dermatitis, With Eric Simpson, MD
2
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
3
Tips on Optimizing HS Biologics, Combinations, and Surgery
4
Why "Normal" Ferritin Can Miss Iron Deficiency, With Jacquelyn Powers, MD, MS
5